[시장보고서]인실리코 임상시험 시장 규모, 점유율, 동향 분석 보고서 : 산업별, 치료 분야별, 단계별, 지역별, 부문별 예측(2025-2030년)

인실리코 임상시험 시장 규모, 점유율, 동향 분석 보고서 : 산업별, 치료 분야별, 단계별, 지역별, 부문별 예측(2025-2030년)

In Silico Clinical Trials Market Size, Share & Trends Analysis Report By Industry, By Therapeutic Area, By Phase, By Region, And Segment Forecasts, 2025 - 2030

상품코드 : 1611025

리서치사 : Grand View Research

발행일 : 2024년 11월

페이지 정보 : 영문 120 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,828,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,311,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,279,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

인실리코 임상시험 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 인실리코 임상시험 시장 규모는 2030년까지 55억 9,000만 달러에 달할 것으로 예상됩니다. 이 시장은 2025-2030년까지 연평균 7.74%의 CAGR로 성장할 것으로 예상됩니다. 기존 임상시험은 연구 수행에 막대한 비용이 필요했습니다. 또한, 안전성과 유효성 부족으로 인해 임상시험에 실패하는 의약품과 의료기기가 많아 임상시험 스폰서에게 막대한 손실을 초래하고 있습니다. 이러한 요인들로 인해 인체에서 의약품과 의료기기의 거동을 이해하기 위한 인실리코 임상시험에 대한 수요가 증가하고 있으며, 인실리코 임상시험은 시뮬레이션 기술을 사용하여 의약품과 의료기기의 효능과 안전성을 이해하고자 합니다.

이것은 부작용의 가능성을 줄이고 연구의 안전성과 유효성을 향상시킬 수 있습니다. 시장 진입 기업들은 사람들에게 새로운 치료법을 제공하기 위해 많은 투자를 하고 있습니다. 예를 들어, 2021년 6월, In Silico Medicine은 In Silico 연구를 통해 신약 개발을 위한 연구개발을 강화하기 위해 2억 5,500만 달러의 자금을 조달했습니다. COVID-19 팬데믹 기간 동안 임상연구시설이 일시적으로 폐쇄되고, 인실리코 연구 모델을 통해 백신 및 COVID-19 치료제 연구가 진행되면서 인실리코 임상시험에 대한 수요도 개선되었습니다. 이러한 조치는 시장 성장에 긍정적인 영향을 미칠 가능성이 높습니다.

인실리코 임상시험 시장 보고서 하이라이트

인실리코 임상시험의 대부분이 전 세계적으로 의료기기를 대상으로 진행되기 때문에 2024년에는 의료기기 부문이 시장을 주도했습니다.
2024년 2단계 부문은 시장 매출 점유율에서 가장 큰 비중을 차지했습니다.
암 치료 분야는 2024년 가장 큰 시장 수익 점유율을 차지했습니다.
암 임상시험은 환자에게 부작용을 일으킬 가능성이 높기 때문에 암에 대한 인실리코(In Silico) 시험에 대한 수요를 촉진하고 있습니다.
북미 시장은 여러 세계 기업이 이 시장에서 사업을 전개하고 있어 2024년 가장 큰 매출 점유율을 차지했습니다.
또한, 미국에서는 많은 인실리코(In Silico) 테스트가 수행되고 있으며, 이는 이 지역 시장의 성장에 더욱 기여하고 있습니다.

지역별 시장 점유율 분석, 2024년과 2030년
지역별 시장 대시보드
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트

제8장 경쟁 구도

기업 분류
기업 시장 상황 분석, 2024년
기업 개요
- Certara, Inc.
- Novadiscovery Sas
- Insilico Medicine, Inc.
- Dassault Systemes SE
- GNS Healthcare Inc.
- The AnyLogic Company
- InSilicoTrials
- Immunetrics Inc.
- Nuventra Pharma Sciences
- Abzena Ltd.

ksm

영문 목차

영문목차

In Silico Clinical Trials Market Growth & Trends:

The global in silico clinical trials market size is anticipated to reach USD 5.59 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 7.74% from 2025 to 2030. Traditional clinical trials require huge expenditure to conduct research. Moreover, a high number of drugs and medical devices fail in the clinical trial owing to the lack of safety and efficacy, which creates huge losses for the clinical trial sponsors. These factors promote the demand for in silico clinical trials, to understand the behavior of drugs or medical devices in humans. In silico clinical trials use simulation techniques to understand the efficacy and safety of a drug or medical device.

This reduces the chances of adverse reactions, thus, improving the safety and efficacy of research studies. The market players are making significant investments to provide new treatments to the people. For instance, in June 2021, In silico Medicine raised USD 255 million in funding to boost its R&D for drug discovery, through in silico studies. The demand for in silico clinical trials was also improved during the pandemic as there was a temporary shutdown of clinical research sites and several studies for vaccines and therapeutic agents for COVID-19 were performed through in silico research models. Such actions are likely to have a positive impact on market growth.

In Silico Clinical Trials Market Report Highlights:

The medical device segment dominated the market in 2024 owing to the fact that the majority of in silico trials are performed for medical devices globally
The phase II segment accounted for the largest market revenue share in 2024
The oncology therapeutic area segment accounted for the largest market revenue share in 2024
The cancer clinical trials have high chances of incurring adverse effects on patients, which promotes the demand for in silico trials for cancer
North America held the largest revenue share in 2024 due to the presence of several global players operating in the market
In addition, a significant number of in silico trials are performed in the U.S., which further contributes to the growth of the regional market

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
1.5. Market Formulation & Validation
1.6. Model Details
- 1.6.1. Commodity Flow Analysis
- 1.6.2. Bottom-up Approach
1.7. List of Secondary Sources
1.8. List of Abbreviations
1.9. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. In Silico Clinical Trials Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
- 3.2.1. Market driver analysis
  - 3.2.1.1. Cost Efficiency Associated with In silico Clinical Trials Compared to Traditional Clinical Trials
  - 3.2.1.2. Growing Trend of Eliminating/Reducing Animal Testing
  - 3.2.1.3. Increasing Technological Advancement in the In silico Clinical Trials Market
- 3.2.2. Market restraint analysis
  - 3.2.2.1. Protein Flexibility Issues, Molecule Conformation and Promiscuity May Hinder Accurate Predictions, thus limiting its Adoption
  - 3.2.2.2. Limited Awareness in the Developing Economies
3.3. Market Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis

Chapter 4. In Silico Clinical Trials Market: Industry Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Global In Silico Clinical Trials Market: Industry Movement Analysis
4.3. Global In Silico Clinical Trials Size & Trend Analysis, by Industry, 2018 to 2030 (USD Million)
4.4. Medical Devices
- 4.4.1. Medical devices market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Pharmaceutical
- 4.5.1. Pharmaceutical market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. In Silico Clinical Trials Market: Therapeutic Area Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Global In Silico Clinical Trials Market: Therapeutic Area Movement Analysis
5.3. Global In Silico Clinical Trials Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
5.4. Oncology
- 5.4.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Infectious Disease
- 5.5.1. Infectious disease market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Hematology
- 5.6.1. Hematology market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Cardiology
- 5.7.1. Cardiology market estimates and forecasts, 2018 to 2030 (USD Million)
5.8. Dermatology
- 5.8.1. Dermatology market estimates and forecasts, 2018 to 2030 (USD Million)
5.9. Neurology
- 5.9.1. Neurology market estimates and forecasts, 2018 to 2030 (USD Million)
5.10. Diabetes
- 5.10.1. Diabetes market estimates and forecasts, 2018 to 2030 (USD Million)
5.11. Others
- 5.11.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. In Silico Clinical Trials Market: Phase Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Global In Silico Clinical Trials Market: Phase Movement Analysis
6.3. Global In Silico Clinical Trials Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)
6.4. Phase I
- 6.4.1. Phase I market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Phase II
- 6.5.1. Phase II market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Phase III
- 6.6.1. Phase III market estimates and forecasts, 2018 to 2030 (USD Million)
6.7. Phase IV
- 6.7.1. Phase IV market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. In Silico Clinical Trials Market: Regional Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. North America
- 7.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.3.2. U.S.
  - 7.3.2.1. Key country dynamics
  - 7.3.2.2. Competitive scenario
  - 7.3.2.3. Regulatory framework
  - 7.3.2.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.3.3. Canada
  - 7.3.3.1. Key country dynamics
  - 7.3.3.2. Competitive scenario
  - 7.3.3.3. Regulatory framework
  - 7.3.3.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.3.4. Mexico
  - 7.3.4.1. Key country dynamics
  - 7.3.4.2. Competitive scenario
  - 7.3.4.3. Regulatory framework
  - 7.3.4.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
7.4. Europe
- 7.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.4.2. UK
  - 7.4.2.1. Key country dynamics
  - 7.4.2.2. Competitive scenario
  - 7.4.2.3. Regulatory framework
  - 7.4.2.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.4.3. Germany
  - 7.4.3.1. Key country dynamics
  - 7.4.3.2. Competitive scenario
  - 7.4.3.3. Regulatory framework
  - 7.4.3.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.4.4. France
  - 7.4.4.1. Key country dynamics
  - 7.4.4.2. Competitive scenario
  - 7.4.4.3. Regulatory framework
  - 7.4.4.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.4.5. Italy
  - 7.4.5.1. Key country dynamics
  - 7.4.5.2. Competitive scenario
  - 7.4.5.3. Regulatory framework
  - 7.4.5.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.4.6. Spain
  - 7.4.6.1. Key country dynamics
  - 7.4.6.2. Competitive scenario
  - 7.4.6.3. Regulatory framework
  - 7.4.6.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.4.7. Denmark
  - 7.4.7.1. Key country dynamics
  - 7.4.7.2. Competitive scenario
  - 7.4.7.3. Regulatory framework
  - 7.4.7.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.4.8. Sweden
  - 7.4.8.1. Key country dynamics
  - 7.4.8.2. Competitive scenario
  - 7.4.8.3. Regulatory framework
  - 7.4.8.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.4.9. Norway
  - 7.4.9.1. Key country dynamics
  - 7.4.9.2. Competitive scenario
  - 7.4.9.3. Regulatory framework
  - 7.4.9.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
7.5. Asia Pacific
- 7.5.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.2. Japan
  - 7.5.2.1. Key country dynamics
  - 7.5.2.2. Competitive scenario
  - 7.5.2.3. Regulatory framework
  - 7.5.2.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.5.3. China
  - 7.5.3.1. Key country dynamics
  - 7.5.3.2. Competitive scenario
  - 7.5.3.3. Regulatory framework
  - 7.5.3.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.5.4. India
  - 7.5.4.1. Key country dynamics
  - 7.5.4.2. Competitive scenario
  - 7.5.4.3. Regulatory framework
  - 7.5.4.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.5.5. Australia
  - 7.5.5.1. Key country dynamics
  - 7.5.5.2. Competitive scenario
  - 7.5.5.3. Regulatory framework
  - 7.5.5.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.5.6. South Korea
  - 7.5.6.1. Key country dynamics
  - 7.5.6.2. Competitive scenario
  - 7.5.6.3. Regulatory framework
  - 7.5.6.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.5.7. Thailand
  - 7.5.7.1. Key country dynamics
  - 7.5.7.2. Competitive scenario
  - 7.5.7.3. Regulatory framework
  - 7.5.7.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
7.6. Latin America
- 7.6.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.6.2. Brazil
  - 7.6.2.1. Key country dynamics
  - 7.6.2.2. Competitive scenario
  - 7.6.2.3. Regulatory framework
  - 7.6.2.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6.3. Argentina
  - 7.6.3.1. Key country dynamics
  - 7.6.3.2. Competitive scenario
  - 7.6.3.3. Regulatory framework
  - 7.6.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
7.7. MEA
- 7.7.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.7.2. South Africa
  - 7.7.2.1. Key country dynamics
  - 7.7.2.2. Competitive scenario
  - 7.7.2.3. Regulatory framework
  - 7.7.2.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.7.3. Saudi Arabia
  - 7.7.3.1. Key country dynamics
  - 7.7.3.2. Competitive scenario
  - 7.7.3.3. Regulatory framework
  - 7.7.3.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.7.4. UAE
  - 7.7.4.1. Key country dynamics
  - 7.7.4.2. Competitive scenario
  - 7.7.4.3. Regulatory framework
  - 7.7.4.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.7.5. Kuwait
  - 7.7.5.1. Key country dynamics
  - 7.7.5.2. Competitive scenario
  - 7.7.5.3. Regulatory framework
  - 7.7.5.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Company Categorization
8.2. Company Market Position Analysis, 2024
8.3. Company Profiles
- 8.3.1. Certara, Inc.
  - 8.3.1.1. Company overview
  - 8.3.1.2. Financial performance
  - 8.3.1.3. Service benchmarking
  - 8.3.1.4. Strategic initiatives
- 8.3.2. Novadiscovery Sas
  - 8.3.2.1. Company overview
  - 8.3.2.2. Financial performance
  - 8.3.2.3. Service benchmarking
  - 8.3.2.4. Strategic initiatives
- 8.3.3. Insilico Medicine, Inc.
  - 8.3.3.1. Company overview
  - 8.3.3.2. Financial performance
  - 8.3.3.3. Service benchmarking
  - 8.3.3.4. Strategic initiatives
- 8.3.4. Dassault Systemes SE
  - 8.3.4.1. Company overview
  - 8.3.4.2. Financial performance
  - 8.3.4.3. Service benchmarking
  - 8.3.4.4. Strategic initiatives
- 8.3.5. GNS Healthcare Inc.
  - 8.3.5.1. Company overview
  - 8.3.5.2. Financial performance
  - 8.3.5.3. Service benchmarking
  - 8.3.5.4. Strategic initiatives
- 8.3.6. The AnyLogic Company
  - 8.3.6.1. Company overview
  - 8.3.6.2. Financial performance
  - 8.3.6.3. Service benchmarking
  - 8.3.6.4. Strategic initiatives
- 8.3.7. InSilicoTrials
  - 8.3.7.1. Company overview
  - 8.3.7.2. Financial performance
  - 8.3.7.3. Service benchmarking
  - 8.3.7.4. Strategic initiatives
- 8.3.8. Immunetrics Inc.
  - 8.3.8.1. Company overview
  - 8.3.8.2. Financial performance
  - 8.3.8.3. Service benchmarking
  - 8.3.8.4. Strategic initiatives
- 8.3.9. Nuventra Pharma Sciences
  - 8.3.9.1. Company overview
  - 8.3.9.2. Financial performance
  - 8.3.9.3. Service benchmarking
  - 8.3.9.4. Strategic initiatives
- 8.3.10. Abzena Ltd.
  - 8.3.10.1. Company overview
  - 8.3.10.2. Financial performance
  - 8.3.10.3. Service benchmarking
  - 8.3.10.4. Strategic initiatives

한글목차

인실리코 임상시험 시장 성장과 동향

인실리코 임상시험 시장 보고서 하이라이트

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 인실리코 임상시험 시장 변수, 동향, 범위

제4장 인실리코 임상시험 시장 : 산업별, 추정·동향 분석

제5장 인실리코 임상시험 시장 : 치료 분야별, 추정·동향 분석

제6장 인실리코 임상시험 시장 : 단계별, 추정·동향 분석

제7장 인실리코 임상시험 시장 : 지역별, 추정·동향 분석